Navigation Links
'Prozac miracle' could end in disaster

A major lawsuit has been launched against the British pharmaceutical giant GlaxoSmithKline on behalf of a group of people who say they became chronically addicted to an antidepressant drug in the same class as Prozac. The case, which has been filed in California, is the first ever to claim damages for addiction against one of the drug companies that have made billions from SSRIs (selective serotonin reuptake inhibitors) - the class of drug of which Prozac is the best known - and which were hailed as "wonderdrugs" when they first hit the market in the 1980s.

// The drug is known as Seroxat in Britain and Paxil in the US. This drug has the generic name-Paroxetine. There are 35 people in the class action at the moment - from a website designer to a bank fraud investigator and a senior airforce officer - but many more are expected to join it. All were prescribed Paxil/Seroxat for mild depression or anxiety and none was told they might become hooked. When they tried to stop taking it, they suffered violent and disturbing symptoms, including jolting pains in the head, vertigo, loss of coordination, abdominal discomfort, flu symptoms, agitation and confusion.

The lawsuit alleges that the manufacturer, GlaxoSmithKline, has deliberately failed to warn doctors and patients that Paxil/Seroxat can cause severe withdrawal reactions. The US lawyers allege that all the SSRI class of antidepressants have the potential to cause withdrawal reactions when people try to stop taking them, but that Paxil/Seroxat is the worst.


'"/>




Page: 1

Related medicine news :

1. Maharashtra warns against Mahims miracle water
2. Virus Level could Predict Cervical Cancer Risk
3. Beware of the oral patch! It could be cancer!!!
4. Wonder drug - could end in disaster
5. Pollution could be a risk
6. Fright could be more harmful
7. Pregnant smokers could harm their child
8. Snoring could be a warning
9. Anthrax drug doxycycline could stunt fetal growth
10. Hike in drug licence fee could hit several SSI units in TN
11. Lengthy Fingers could predict heart attacks

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Prozac miracle could end disaster

(Date:11/25/2009)...RNewswire/--TheBartleHallConventionCenterwilltempo...-10,whenKansasCityhoststhelatestinaseriesofmassive...iceventhasthepotentialtobethebiggestoneyet,because...weekdaysinsteadofoveraweekend,"SheriWood,executive...toftheNationalAssociationofFreeClinics(NAFC). ,...
(Date:11/25/2009)...re/-SentinelleMedicalInc.,aleadingmanufacturerofbr...esasuiteofnewleadingedgeclinicalapplicationsonitsA...RadiologicalSocietyofNorthAmerica(RSNA)annualmeeti...applicationsleveragetheuniquehighqualityimagesgene...pportmultipleimagingmodalitiesformulti-parametrica...
(Date:11/25/2009)...swire-USNewswire/--TheBlackAIDSInstituterecentlyhe...ershipfor2010. ,, ThenewBoardMembersareahighlyd...law,finance,governmenthealthprograms,editorial,and...erangeofpersonalbackgroundsincludingbothheterosexu...es,andrepresentingmultipleagegroups. ,, (Photo:...
(Date:11/25/2009)...ular cancer who were treated with cisplatin-based ...ng neurological side effects and Raynaud-like phen...rapy, according to a new study published online No...nstitute . , Marianne Brydy, M.D., of the Depart...n Bergen, Norway, and colleagues conducted a cross...
(Date:11/25/2009)...essure? This simple question has been the focus o...ated gene Modulates High Blood Pressure in Mice & ...imple question has been the focus of intense resea...first time established a link between a novel gene...ress in mice as well as humans. The studies were d...
Breaking Medicine News(10 mins):Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:New stress-related gene modulates high blood pressure in mice and men 2
... at reducing problems in heart transplant patients...y the drug reduced the incidence of a serious diso...wn as coronary vasculopathy.// Previous studi... University in Philadelphia conducted a study to d...
...nerable to serious brain injuries when they fall t...tigators distinguish between accidental and intent...a study found that rotational forces generated by ...issue and alter brain function, and nerve cell dam...
...ly common procedure for hard-to-treat cancers. The...take months or even years for stem cells// to beco...is at risk for serious infection. Now, researchers...experimental treatment. In Ed Bauters case...
...t sperm as they get older //and they found to thei...perm an edge. The deformed sperm increase the r...less are likely to beat out their healthy counterp...e is more common in children born to older fathers...
...thma attacks be causing the very thing it aims to ... School of Public Health and Brigham and Women’s H...wn as beta-agonists in asthmatics. Beta-ago...pill or liquid form, delivered in a nebulizer, or ...
...ath rate from it is falling due to early detection...versity of Southern Denmark carried out an analysi...ween 1993 and 1999. While the proportion of pe...Commenting on the findings published in this week'...
Other Medicine News:
(Date:11/25/2009)...inker.comannouncesthatanewmarketresearchreportisav...ry-USMarketTrends&Analysis http://www.reportl...arket-Trends--Analysis.html ,, TheUSintranasal...uticapplicationsfromthedeliveryofconventionallocal...drugs.Thefutureofthetechnologyhingesontotheeffecti...
(Date:11/25/2009)...re/-- ChemoCentryx,Inc.,announcedtodaythatPhaseII...ectiveRandomizedOralTherapyEvaluationinCrohn,sdise...moderate-to-severeCrohn,sdiseasedemonstratedclinic...le.Thestudydemonstratedevidenceofclinicalefficacyi...decreaseintheCrohn,sDiseaseActivityIndex(CDAI)inpa...
(Date:11/24/2009)...stCall/--Endologix,Inc.(Nasdaq: ELGX ),developerof...uncedtodaythatithasfiledamotiontostay,ordiscontinu...ghtagainstitinOctober2009byCook,Inc.Themotionwasfi...diana. ,, Endologixhasrequestedthatthestayremai...ice(USPTO)conductsproceedingstore-examinethetwopat...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 1Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 3National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 1National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 2National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 3National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 4National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 5Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 1Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 2Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 3Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 4Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 5Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 6Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 7Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 8Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 9Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 10
...linical program to evaluate PROMUS(TM) Element(TM)...3 Boston Scientific Corporation (NYSE: BSX ) to...in the PLATINUM clinical trial, which is designed ...verolimus-Eluting Coronary Stent. The first U.S. ...er of the Rockies in Loveland, Colorado by Thomas ...
...NG-WEIHENSTEPHAN, Germany, February 3 Pieris AG, ...R), a novel class of targeted,human protein therap...,progress in the development of its Anticalin(R) c...oad therapeutic applicability. , Having succes...in vitro,and in vivo, Pieris has now validated the...
Other Medicine Technology:Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 2Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 3Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 4Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 5Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist 2Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist 3
Alkaline Phosphatase
Uric Acid (Uricase) (Single Reagent)
Uric acid FS TBHBA
Uric Acid
Medicine Products: